CN111315360B - 树脂毒素制剂 - Google Patents

树脂毒素制剂 Download PDF

Info

Publication number
CN111315360B
CN111315360B CN201880072756.3A CN201880072756A CN111315360B CN 111315360 B CN111315360 B CN 111315360B CN 201880072756 A CN201880072756 A CN 201880072756A CN 111315360 B CN111315360 B CN 111315360B
Authority
CN
China
Prior art keywords
rtx
formulation
ethanol
free formulation
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880072756.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN111315360A (zh
Inventor
B·琼斯
亚历西斯·拿哈马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorento Pharmaceutical Co ltd
Sorrento Therapeutics Inc
Original Assignee
Sorento Pharmaceutical Co ltd
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorento Pharmaceutical Co ltd, Sorrento Therapeutics Inc filed Critical Sorento Pharmaceutical Co ltd
Publication of CN111315360A publication Critical patent/CN111315360A/zh
Application granted granted Critical
Publication of CN111315360B publication Critical patent/CN111315360B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880072756.3A 2017-09-11 2018-09-11 树脂毒素制剂 Active CN111315360B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762556824P 2017-09-11 2017-09-11
US62/556,824 2017-09-11
PCT/IB2018/056944 WO2019049112A1 (en) 2017-09-11 2018-09-11 RESINIFERATOXIN FORMULATION

Publications (2)

Publication Number Publication Date
CN111315360A CN111315360A (zh) 2020-06-19
CN111315360B true CN111315360B (zh) 2025-01-17

Family

ID=63708422

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880072756.3A Active CN111315360B (zh) 2017-09-11 2018-09-11 树脂毒素制剂

Country Status (9)

Country Link
US (3) US20190076396A1 (cg-RX-API-DMAC7.html)
EP (1) EP3681472A1 (cg-RX-API-DMAC7.html)
JP (2) JP7358337B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200051771A (cg-RX-API-DMAC7.html)
CN (1) CN111315360B (cg-RX-API-DMAC7.html)
AU (1) AU2018327301B2 (cg-RX-API-DMAC7.html)
CA (1) CA3074951A1 (cg-RX-API-DMAC7.html)
MX (2) MX2020002692A (cg-RX-API-DMAC7.html)
WO (1) WO2019049112A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
WO2020226370A1 (ko) 2019-05-09 2020-11-12 주식회사 엘지화학 전기화학소자용 분리막 및 이를 포함하는 전기화학소자
US20230143545A1 (en) * 2020-03-30 2023-05-11 Board Of Regents Of The University Of Nebraska Treating Pulmonary Inflammatory Disease Associated With Covid-19 By Administering Resiniferatoxin
ES3004508T3 (en) * 2020-04-15 2025-03-12 Gruenenthal Gmbh Resiniferatoxin compositions
WO2021257956A1 (en) * 2020-06-19 2021-12-23 Sorrento Therapeutics, Inc. Administration of resiniferatoxin for treatment of bladder pain or bladder cancer
EP4291174A1 (en) * 2021-02-11 2023-12-20 Sorrento Therapeutics, Inc. Administration of resiniferatoxin for treatment of prostate cancer
US20250228765A1 (en) 2024-01-15 2025-07-17 Gruenenthal Gmbh Treating knee joint pain by injecting resiniferatoxin at ultra low doses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101119713A (zh) * 2004-11-24 2008-02-06 阿尔高克斯制药公司 类辣椒素凝胶制剂及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187193B (en) 1986-02-27 1989-11-08 Gerald Scott Controllably and swiftly degradable polymer compositions and films and other products made therefrom
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5232684A (en) 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
NZ540769A (en) * 2002-12-18 2009-03-31 Algorx Pharmaceuticals Inc Administration of capsaicinoids for the treatment of pain
EP1838301B1 (de) * 2004-12-28 2015-01-28 Mestex AG Verwendung von resiniferatoxin (rtx) für die herstellung eines mittels zur behandlung von schmerzen
ES2384244T3 (es) * 2004-12-28 2012-07-02 Mestex Ag Utilización de un agonista del receptor vaniloide juntamente con un glicosaminoglicano o un proteoglicano para la fabricación de un fármaco para el tratamiento de los dolores articulares y procedimiento para la aplicación de este fármaco
US9956166B2 (en) * 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
CN113490745A (zh) * 2018-12-21 2021-10-08 索伦托药业有限公司 神经周施用树脂毒素治疗适应不良性疼痛
WO2020154261A1 (en) * 2019-01-22 2020-07-30 Sorrento Therapeutics, Inc. Method for treating osteoarthritis pain by administering resiniferatoxin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101119713A (zh) * 2004-11-24 2008-02-06 阿尔高克斯制药公司 类辣椒素凝胶制剂及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
("Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control";Laszlo Karai et al.;《The Journal of Clinical Investigation》;20040531;第113卷(第9期);第1344-1352页 *

Also Published As

Publication number Publication date
KR20200051771A (ko) 2020-05-13
US20220370405A1 (en) 2022-11-24
AU2018327301A1 (en) 2020-04-09
AU2018327301B2 (en) 2024-08-22
CA3074951A1 (en) 2019-03-14
MX2020002692A (es) 2020-10-14
MX2022013947A (es) 2022-11-30
JP2020533336A (ja) 2020-11-19
EP3681472A1 (en) 2020-07-22
JP7358337B2 (ja) 2023-10-10
WO2019049112A1 (en) 2019-03-14
US20250000842A1 (en) 2025-01-02
JP2022176377A (ja) 2022-11-25
CN111315360A (zh) 2020-06-19
US20190076396A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
JP7358337B2 (ja) レシニフェラトキシンの製剤
KR101593579B1 (ko) 치료용 조성물
DE69808695T2 (de) Stabile Insulinformulierungen
Singh et al. Formulation development & evaluation of topical gel formulations using different gelling agents and its comparison with marketed gel formulation
DE68903814T2 (de) Etoposid-loesungen.
RU2613490C2 (ru) Композиция на основе R(-)-празиквантела для лечения и профилактики гельминтозов у теплокровных
JP2010132607A (ja) アトピー性皮膚炎治療用軟膏剤
CN101322688A (zh) 供静脉用氟马西尼的水包油乳剂及制备方法
AT515356B1 (de) Stabile alkoholische Lösung von Alprostadil
CN104771360B (zh) 一种蒿甲醚纳米乳药物组合物及其制备方法
CN103705459A (zh) 一种结晶性头孢噻呋游离酸纳米乳注射剂及其制备方法
CN101711739B (zh) 卡马西平的口服药物组合物
AU2020203541A1 (en) Compositions comprising quillaja extract and methods of preparations and use thereof
CN110494129B (zh) 一种乙酰氨基阿维菌素纳米乳及其制备方法和用途
PÉrez-Lozano et al. Application of a validated method in the stability study of colistin sulfate and methylparaben in a veterinary suspension formulation by high-performance liquid chromatography with a diode array detector
De Vito et al. Pharmacokinetics of metoclopramide after intraarterial, intramuscular, subcutaneous, and perrectal administration in rabbits
BR102021002197A2 (pt) Método de tratamento, uso e composição veterinária injetável tixotrópica para liberação controlada de doramectina e vitamina e
CN116528834A (zh) 蛋白质结合大麻素制剂及其用途
RU2320365C2 (ru) Фармацевтическая композиция
DE10234784A1 (de) Intravenös applizierbare, pharmazeutische Darreichungsform
US20210085802A1 (en) Nanoparticle pharmaceutical delivery system
Shah et al. Physical, chemical, and bioavailability studies of parenteral diazepam formulations containing propylene glycol and polyethylene glycol 400
KR20090028977A (ko) N,n-디에칠니코틴아마이드 또는 살리실산 나트륨을이용한 극난용성 약물의 싱크조건 유지를 위한 가용화조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information
CB02 Change of applicant information

Address after: California, USA

Applicant after: Sorento Pharmaceutical Co.,Ltd.

Address before: California, USA

Applicant before: Sorrento Therapeutics, Inc.

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant